Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Rheumatology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Connective Tissue Diseases Clinical Trials

A listing of Connective Tissue Diseases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (45) clinical trials

Prevalence of Sarcopenia and Undernutrition in Patients With Cirrhosis and Abdominal Hernia

Sarcopenia is a common condition in patients with cirrhosis, with a prevalence of around 50%. It is unknown if the presence of sarcopenia may influence the prevalence of abdominal hernias in this group of patients. Clinical, nutritional and radiological evaluation will be performed in two groups of cirrhotic patients to ...

Phase N/A

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these ...

Phase N/A

Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis

A phase I dose-escalating clinical trial will be conducted to determine the safety and tolerability of a single intra-articular injection (into the knee joint) of autologous tolerogenic dendritic cells, and to enable selection of a suitable dose regimen for phase II trial. The primary objective of the phase I study ...

Phase

Yellow Fever Vaccine in Patients With Rheumatic Diseases

According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans. In view of this, vaccination is suitable for residents and travelers to the risk area. However, for immunosuppressed patients there is a formal recommendation not to vaccinate with ...

Phase N/A

Effect of Synbiotic on Immune Response Gut Permeability and Microbiota in Patient With Connective Tissue Disease

Study showed gut microbiota has a role in the pathogenesis of autoimmune diseases. Gut microbiota which can increase gut permeability affect the antigen presentation to the immune system. Synbiotic supplementation is expected to improve immune system, gut permeability, and gut microbiota in patients with connective tissue disease. The subjects who ...

Phase N/A

Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment

Liver cirrhosis is a chronic disease characterized by a progressive accumulation of fibrosis, loss of liver function and portal hypertension leading to several hemodynamic changes.The exact pathophysiological mechanisms causing the hyperdynamic alterations in cirrhosis are not fully elucidated. Aim The aim of the study is to assess hemodynamic alterations in ...

Phase N/A

MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis

Background Standardization and new therapeutic treatments of variceal bleeding has significantly reduced the mortality the last 25 years, but there is still a high 6-week mortality around 15-20% and 1-year mortality of about 40%. Cirrhotic patients without prophylactic treatment suffer a risk of 60% of re-bleeding within the first year ...

Phase N/A

Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)

Objectives To detect pulmonary hypertension amongst patients with connective tissue diseases through systematic screening To understand the prevalence of pulmonary hypertension in Chinese patients with connective tissue diseases Study design: The study is a territory-wide pulmonary hypertension screening project. Patients fulfilling the inclusion and exclusion criteria will undergo screen echocardiography ...

Phase N/A

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

The effects of visible light, while common in the environment (visible spectrum accounts for 44% of total solar energy), remain undefined. An important safety feature of visible red light (600 nm to 700 nm) is that it does not generate pro-carcinogenic DNA damage as does ultraviolet (UV) light. Recently published ...

Phase

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages. In a dose escalation stage, approximately ...

Phase